Belgium biotech company translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, Agomab is building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.
Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers. The second TGF-ß-targeting drug candidate, AGMB-447, is a lung-restricted ALK-5-inhibitor in development for treatment of idiopathic pulmonary fibrosis. AGMB-101 is a full agonist against the MET receptor in development for the treatment of organ failure. Both of these preclinical candidates, AGMB-447 and AGMB-101, are currently in IND-enabling studies. Additionally, Agomab recently expanded its research pipeline with a partial MET-receptor agonist, AGMB-102, for a range of fibrotic indications.
Location: Belgium, East Flanders, Ghent
Employees: 11-50
Total raised: $312.25M
Founded date: 2017
Investors 5
Date | Name | Website |
- | V-Bio Vent... | v-bio.vent... |
21.07.2022 | Asabys Par... | asabys.com... |
- | Andera Par... | anderapart... |
- | Omnes Capi... | omnescapit... |
- | Pontifax V... | pontifax.c... |
Funding Rounds 4
Date | Series | Amount | Investors |
13.10.2023 | Series C | $100.63M | - |
13.07.2022 | Series B | $114M | Asabys Par... |
10.03.2021 | Series B | $74M | V-Bio Vent... |
03.04.2019 | Series A | $23.61M | - |
Mentions in press and media 15
Date | Title | Description | Source |
13.10.2023 | Agomab Therapeutics secures €94.9M in Series C to advance dr... | This week, Belgium medtech company Agomab Therapeutics announced the closing of a €94.9 million Seri... | tech.eu/20... |
11.10.2023 | Agomab Raises $100M in Series C Funding | Agomab, a Ghent, Belgium-based biology treatments company, raised $100M in Series C funding. The ro... | finsmes.co... |
11.10.2023 | Agomab adds $100M in series C funds to push ALK5 inhibitor t... | A week after entering its lead asset into a phase 2 trial for a type of Crohn’s disease, Agomab Ther... | fiercebiot... |
11.10.2023 | Belgian biotech company Agomab Therapeutics raises €94.9M to... | Read this article in: Ghent, Belgium-based Agomab Therapeutics, a biotech company, announced on Wed... | siliconcan... |
11.10.2023 | Agomab Raises $100 Million Series C to Advance Fibrosis-focu... | Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Seri... | anderapart... |
11.10.2023 | Agomab, participada de Asabys, cierra una Series C de $100M ... | 11/10/2023 Nota de prensa GOMAB, PARTICIPADA DE ASABYS, CIERRA UNA SERIES C DE $100M CON FIDELITY,... | webcapital... |
13.07.2022 | Agomab Raises Additional $40.5 Million Through Series B Exte... | Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with ... | anderapart... |
13.07.2022 | Pfizer jumps into bed with Agomab, leading series B extensio... | Pfizer is throwing its weight behind Agomab Therapeutics, leading a $40.5 million extension to a ser... | fiercebiot... |
28.10.2021 | Agomab Therapeutics to Acquire Origo Biopharma | Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement un... | anderapart... |
28.10.2021 | Agomab Therapeutics adquiere Origo Biopharma, participada po... | 28/10/2021 Nota de prensa AGOMAB THERAPEUTICS ADQUIERE ORIGO BIOPHARMA, PARTICIPADA POR ASABYS. •... | webcapital... |
Show more